The Center for Innovative NeuroTech Advancement (CINTA) & NeuroTech Harbor (NTH) Announce the Cycle 5 Award Competition

Supported by the NIH Blueprint MedTech Incubator Hubs Program

Blueprint MedTech Incubator Hubs

"Center without Walls"

To accelerate the development of emerging, ground-breaking technologies into first-in-human studies along the path to being commercially viable, clinically focused solutions for disorders involving the nervous system.

> CINTA (Center for Innovative Neurotech Advancement), a program within CIMIT (Steve Schachter, MD as PI and Paolo Bonato, PhD as co-PI from Spaulding Rehabilitation Hospital).



 NTH (NeuroTech Harbor), a partnership between Johns Hopkins University (contact PI - Sri Sarma, PhD) and Howard University (PI - Evaristus Nwulia, MD).



Blueprint MedTech Incubator Hubs Overview: Types of Awards

Awards to date: 54 Funding awarded: \$25.6M



Optimizer awards

- Will rarely exceed \$500,000 in direct costs per year for a period of up to 4 years.
- In addition to monetary support, awardees will work with their executive mentor regularly to focus on business, regulatory, clinical, and technical factors that may impede commercialization.
- Resources to plan and support early translational activities such as prototype development, engineering design, regulatory, reimbursement, and intellectual property planning.

Seedling awards

- Provide support for six months, a \$25,000 stipend, and \$25,000 to hire subject matter experts.
- Mentors will work with awardees to help resolve identified gaps on the path to commercialization.
- If the gaps are addressed, project teams are eligible for re-assessment in Blueprint Evaluation process or encouraged to pursue other funding opportunities.

Resources Available to Investigators listed on the <u>Blueprint MedTech website</u>

Design, Prototyping, Risk Analysis

- Electronics Manufacturing
- Prototype Manufacturing
- Design Optimization and Risk
- Computational Modeling

Bench and Safety Testing

- Electrical Safety
- Electromagnetic Compatibility
- MR Testing
- Software
- Cybersecurity
- Shelf-life Testing

Biocompatibility and Animal Studies

- Biocompatibility Testing
- Materials characterization and analytical chemistry
- Sterilization testing/validation
- Preclinical Animal Testing (GLP)
- Preclinical Animal Testing (non-GLP)
- Cadaver Testing

Clinical

- · Clinical trial planning
- Biostatistics
- Data Management
- Neuroethics

Resourcesprovided by:•HubsCINTANTHNTH•ContractsActuated MedicalPPD CRO

Business Development

- Public-Private Partnerships CRA, MTA
- Entrepreneurship
- Business Development
- Market / User Research
- Commercialization

Regulatory, Compliance, Quality System

- Regulatory Advising
- QMS Quality Management System setup and audits
- GMP Good Manufacturing Practice setup and audits
- Compliance
- Legal Intellectual Property

Eligibility

The Blueprint Hubs and NIH encourage applications from women, under-represented racial and ethnic groups, as well as individuals with disabilities. Principal Investigators (PIs) from academic institutions, industry or non-profit organizations are invited to apply. Foreign applicants may apply.

Academic PIs must hold a faculty appointment at an institution of higher education or medical center.

PIs from industry or non-academic non-profits are not required to hold a faculty appointment.

Pre-proposal Applications

Applications must focus on a disorder of the nervous system in an area of interest of the **NIH Participating Institutes/Centers for the Blueprint MedTech: Incubator Hubs program**. Applications outside the mission of these participating Institutes/Centers will be not responsive to this solicitation and therefore not advance to full proposal stage.

Contact Institute Program Officer for questions about **mission fit only**, hub staff for other solicitation questions. (<u>https://neuroscienceblueprint.nih.gov/neurotherapeutics/blueprint-medtech/blueprint-medtech-ics-and-contacts</u>)

Participating Centers and Institutes

- National Institute of Biomedical Imaging and Bioengineering (NIBIB),
- National Center for Complementary and Integrative Health (NCCIH),
- National Eye Institute (NEI),
- National Institute on Aging (NIA),
- National Institute on Alcohol Abuse and Alcoholism (NIAAA),
- National Center for Medical Rehabilitation Research at the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD),
- National Institute on Drug Abuse (NIDA),
- National Institute of Dental and Craniofacial Research (NIDCR),
- National Institute of Mental Health (NIMH),
- National Institute of Neurological Disorders and Stroke (NINDS), and
- Office of Behavioral and Social Sciences Research (OBSSR)
- Helping to End Addiction Long-Term (HEAL)

Note: The National Institute of Child Health and Human Development (NICHD) will only accept applications related to the mission of the National Center for Medical Rehabilitation Research.

Review Process

Applicants must first submit **pre-proposals**, which will undergo review by NIH program scientific staff for eligibility, including mission fit and alignment with program scope. Preproposals are submitted through a simple online application form equivalent to about 4 pages (CoLab).

> A subset of the applicants who submit pre-proposals will be selected to submit **full proposals** which are submitted through the same online application system. The online full proposal form is equivalent to approximately 10 pages.

> > A subset of the applicants who submit full proposals will be selected to participate in a **"deep dive"** evaluation, which is the final stage of **due diligence** review prior to **Optimizer Award** funding decisions.

> > > *sections of the form have word limits and there is an upload with a page limit, but there is not an overall page limit per se.

Pre-Proposal Application Sections

- 1) Applicant Information
- 2) Solution Information
 - Medical Condition (select from list)
 - Technology (select from list)
 - Clinical Need & Standard of Care (<250 words)
 - Stage of Technical Development (select from list)
 - Solution Description (<250 words)
 - Supporting Information and/or References Upload 1 page PDF

3) **Project Information**

- Project Duration
- Proposed Scope of Work (<250 words)
- Regulatory Classification (select from list)
- Regulatory Pathway (<150 words)

Applications that will NOT be considered

- Products not regulated by the FDA.
- Fundamental basic/applied research prior to proof of concept.
- Device technologies that do not significantly advance the state of the art (e.g. device technology that proposes minor modifications to FDAapproved/cleared medical device technology)
- Animal model development: all *in vivo* animal models must be wellestablished and characterized, and available to the applicant.
- Projects focused on technologies for functional augmentation of healthy individuals.



Additional Application Information

- If your project addresses a mental health disorder, you are encouraged to provide preliminary data that uses quantitative, objective measures for outcomes. Please incorporate these measures into your proposal.
- Only IRB-exempt or minimal-risk clinical studies can be proposed for funding, and only if minimal risk studies can be conducted at Georgia Tech's HomeLab, one of the core resources of the Blueprint Medtech program.
- Hubs cannot support safety or effectiveness studies.

https://cacp.gatech.edu/research/accessibility/HomeLab



NIH Definition of IRB-Exempt Human Subjects Research

https://grants.nih.gov/sites/default /files/exemption_infographic

NIH Exempt Human Subjects Research		8 Exemptions				
Meets the definition of human subjects research. Exempt studies involve human subjects research: research involving a living individual about whom data or biospecimens are obtained/used/studied/analyzed through interaction/intervention, or identifiable, private information is used/studied/analyzed/generated						
2 Meets the criteria of one of the following exemptions:						
Exemption 1: conducted in an educational setting using normal educational practices* *Cannot include any other procedures, such as collection of clinical data or biospecimens	Exempt educational interviews, or public *Limited IRB rev	Exemption 2: uses educational tests, surveys, interviews, or observations of public behavior* *Limited IRB review may be required.		Exemption 3: benign behavioral interventions in adults* *Limited IRB review may be required.		
Exemption 4: involves the collection/study of data or specimens if publicly available, or recorded such that subjects cannot be identified* *May be identifiable in limited cases. See §46.104(d)(4)(iii) and (iv)	Exemption demonstra designed to improve, or public ben pro *Applies to projects	Exemption 5: research or demonstration projects designed to study, evaluate, improve, or examine an <i>NIH</i> public benefit or service program* *Applies to projects that NIH itself administers		Exemption 6 : taste and food quality evaluations		
Exemption identifiable biospecimen research use and <i>limited</i> req	Exemption research use information o Broad conse IRB review	Exemption 8 : secondary research use of identifiable information or biospecimens. <i>Broad consent</i> and <i>limited</i> <i>IRB review</i> are required				
For more information see the <u>NIH OER Human Subjects Research website</u> . Send questions/comments to <u>OER-HS@nih.gov</u> .						

What is the definition of minimal risk?

Minimal Risk to subjects means that the probability and magnitude of harm or discomfort anticipated in the research are not greater than those ordinarily encountered in daily life or during the performance of routine physical and psychological examinations or tests and that confidentiality is adequately protected. This category includes protocols that pose "no greater than minimal risk" according to federal regulations.

Examples of Minimal Risk are:

- Study poses no more risk than expected in daily life (e.g., blood draw, physical exam, routine psychological testing).
- Electrophysiological studies in healthy subjects or clinical populations (surface recordings such as EEG, ERP, MEG)
- Non-invasive imaging (e.g., MRI and fMRI) in healthy subjects or clinical populations to investigate basic mechanisms of brain function.

https://www.nimh.nih.gov/funding/clinical-research/nimh-guidance-on-risk-based-monitoring

Lessons Learned from Previous Cycle Submissions Common Reasons for Rejection

Stage of Maturity

- Too early (no proof of concept)
- Too advanced (ready for clinical trials; candidate for UG/UH3 or U44)

Team Composition

- Lacking too many critical areas of expertise
- No evidence of clinical collaboration

• Impact

- Not significantly different from existing products
- Only marginal impact on clinical condition
- Mission fit
 - Not priority area of NIH participating institutes/centers



Summary Information





- The initial anticipated performance period is 12 months, which can be renewed for up to an additional three 12-month periods with CINTA, NTH, and NIH approval.
- The final aim of Hub optimizer projects should be a prototype ready for first-in-human studies.
- Upon successful completion of the project, teams should either have non-governmental funding secured or be ready for entry into the companion translator solicitations from NIH:
 - Blueprint MedTech: Translator (UG3/UH3)
 - Blueprint Medtech: Small Business Translator
 (U44)
- **Seedling awards** provide support for six months, a \$25,000 stipend, and \$25,000 to hire subject matter experts.

Timeline



General Application Information

Applicants should review and be familiar with the program solicitation and FAQs before completing this application.

Solicitation link: https://blueprintneurotech.org/

FAQ link: https://blueprintneurotech.org/faq

Please send questions to info@blueprintneurotech.org.

Sign up for webinar and office hours!



Contacts and Additional Resources

Webinar Slides/Schedule: <u>https://www.cimit.org/web/center-for-innovative-neurotech-advancement/events</u>

FAQs: https://blueprintneurotech.org/faq

All application related questions: info@blueprintneurotech.org 617-643-3800

Office Hours:

For Scheduling Only - Tina Cavaluzzi <u>tcavaluzzi@jhu.edu</u> Availability: 15 minute sessions with program leaders Thursday, Sept 12: 3-5 PM ET Friday, Sept 20: 2:30-4:30 PM ET Wednesday, Sept 25: 3-5 PM ET Wednesday, Oct 2: 2-4 PM ET



Good Luck!